Guangdong Taienkang Pharmaceutical Co., Ltd.

SZSE:301263 Stock Report

Market Cap: CN¥5.8b

Guangdong Taienkang Pharmaceutical Future Growth

Future criteria checks 5/6

Guangdong Taienkang Pharmaceutical is forecast to grow earnings and revenue by 35.3% and 22.9% per annum respectively. EPS is expected to grow by 35.2% per annum. Return on equity is forecast to be 17.3% in 3 years.

Key information

35.3%

Earnings growth rate

35.2%

EPS growth rate

Pharmaceuticals earnings growth18.6%
Revenue growth rate22.9%
Future return on equity17.3%
Analyst coverage

Low

Last updated16 Sep 2024

Recent future growth updates

No updates

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Sep 03
Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Aug 23
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Jul 22
Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

May 22
Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Feb 26
Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

SZSE:301263 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,362378N/A3362
12/31/20251,121296N/A2682
12/31/2024914223N/A1672
6/30/2024751137-15348N/A
3/31/2024756154-19117N/A
12/31/2023761160-10694N/A
9/30/20237911897102N/A
6/30/202381420646155N/A
3/31/202379417345148N/A
1/1/202378317559149N/A
9/30/202275916876160N/A
6/30/202271214049112N/A
3/31/202269715793142N/A
1/1/202265412075120N/A
9/30/202166112446113N/A
6/30/202166812753123N/A
3/31/202167013338121N/A
12/31/202070916132126N/A
9/30/202066213856116N/A
6/30/202061211979120N/A
3/31/20205658795118N/A
12/31/2019496556775N/A
9/30/2019496564256N/A
6/30/2019512694062N/A
3/31/2019523764473N/A
12/31/2018514743969N/A
9/30/2018486711351N/A
6/30/201848067944N/A
3/31/201845758N/A27N/A
12/31/201745055N/A23N/A
9/30/201743043N/A27N/A
6/30/201740835N/A21N/A
3/31/201737831N/A-10N/A
12/31/201636728N/A2N/A
9/30/201638238N/A10N/A
6/30/201639849N/A19N/A
3/31/201638445N/A17N/A
12/31/201537042N/A16N/A
9/30/201533736N/AN/AN/A
6/30/201530429N/A7N/A
3/31/201530535N/A28N/A
12/31/201430440N/A25N/A
12/31/201328048N/A19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301263's forecast earnings growth (35.3% per year) is above the savings rate (2.9%).

Earnings vs Market: 301263's earnings (35.3% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 301263's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301263's revenue (22.9% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 301263's revenue (22.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301263's Return on Equity is forecast to be low in 3 years time (17.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y